Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: A randomized controlled phase 1/2 trial in adults

Journal of Infectious Diseases

Volumn 201, Issue 11, 2010, Pages 1644-1653

  Langley, Joanne M ^a   Frenette, Louise ^c   Ferguson, Linda ^b   Riff, Dennis ^d   Sheldon, Eric ^e   Risi, George ^f   Johnson, Casey ^g   Li, Ping ^h   Kenney, Richard ^h   Innis, Bruce ^h   Fries, Louis ^h  

^a DALHOUSIE UNIVERSITY   (Canada)

^b Colchester Research Group ^*  (United States)

^c QandT Research Inc   (Canada)

^d Advanced Clinical Research Institute   (United States)

^e MIAMI RESEARCH ASSOCIATES   (United States)

^f Infectious Disease Specialists   (United States)

^g Johnson County Clin Trials   (United States)

^h GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INFLUENZA VIRUS A H5N1 VACCINE; TOCOPHEROL; UNCLASSIFIED DRUG; VIRUS HEMAGGLUTININ;

ADULT; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD SAMPLING; BODY TEMPERATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; HEAT EXHAUSTION; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLUENZA; INFLUENZA VIRUS A H5N1; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE STRAIN; MYALGIA; NAUSEA; NOSE CONGESTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEROCONVERSION; SIDE EFFECT; SINUSITIS; SORE THROAT; UPPER RESPIRATORY TRACT INFECTION;

EID: 77951883155     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/652701     Document Type: Article

References (31)

1. Fraser C, Donnelly CA, Cauchemez S, et al. Pandemic potential of a strain of influenza A (H1N1): early findings. Science 2009; 324: 1557-1561
2. World Health Organization (WHO). Cumulative number of confirmed cases of avian influenza A (H5N1) reported to WHO. Vol.2009. Geneva: WHO, 2009.
3. Melidou A, Gioula G, Exindari M, Chatzidimitriou D, Diza-Mataftsi E. Influenza A(H5N1): an overview of the current situation. Euro Surveill 2009; 14: 19, 216.
4. Jennings LC, Monto AS, Chan PK, Szucs TD, Nicholson KG. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis 2008; 8: 650-658
5. Stephenson I, Gust I, Pervikov Y, Kieny MP. Development of vaccines against influenza H5. Lancet Infect Dis 2006; 6: 458-460
6. World Health Organization (WHO). Options for the use of human H5N1 influenza vaccines and the WHO H5N1 stockpile. WHO scientific consultation October 1-3, 2007. Geneva: WHO, 2007.
7. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006; 354: 1343-1351
8. Schwartz B, Wortley P. Mass vaccination for annual and pandemic influenza. Curr Top Microbiol Immunol 2006; 304: 131-152
9. European Committee for the Evaluation of Medicinal Products. Guideline on dossier structure and content for pandemic influenza vaccine marketing authorization application. EMEA/CPMP/VEG/4717/2003. 2008.
10. Bresson JL, Perronne C, Launay O, et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase 1 randomised trial. Lancet 2006; 367: 1657-1664
11. European Committee for the Evaluation of Medicinal Products. Guideline on influenza vaccine prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context. EMEA/CHMP/VWP/263499/ 2006. 2007.
12. Nicholson KG, Colegate AE, Podda A, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/ 97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001; 357: 1937-2013
13. Atmar RL, Keitel WA. Adjuvants for pandemic influenza vaccines. Curr Top Microbiol Immunol 2009; 333: 323-414
14. Osterhaus AD. Pre- or post-pandemic influenza vaccine? Vaccine 2007; 25: 4983-4991
15. Bernstein DI, Edwards KM, Dekker CL, et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 2008; 197: 667-675
16. Chu D-S, Drame M, Hwang S-J. Safety and immunogenicity of an AS adjuvanted H5N1 prepandemic influenza vaccine: a phase 111 study in a large population of Asian adults [abstract VI-3]. In: Program and abstracts of the Xth International Symposium on Respiratory Viral Infections (Singapore). New York: The Macrae Group, 2008.
17. Leroux-Roels I, Bernhard R, Gérard P, Dramé M, Hanon E, LerouxRoels G. Broad clade 2 cross-reactive immunity induced by an adju-vanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One 2008; 3:e1665.
18. Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370: 580-589
19. GlaxoSmithKline. First pre-pandemic vaccine approved to help protect against pandemic influenza: GSK's Prepandrix™ obtains first EU authorisation for a pre-pandemic H5N1 vaccine. Vol.2009. 19 May 2008.
20. Leroux-Roels G. Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data. Expert Opin Biol Ther 2009; 9: 1057-1071
21. Hehme N, Engelmann H, Kuenzel W, Neumeier E, Saenger R. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res 2004; 103: 163-171
22. Kendal AP, Pereira MS, Skehel JJ. Hemagglutination inhibition. In: Kendal AP, Pereira MS, Skehel JJ, eds. Concepts and procedures for laboratory-based influenza surveillance. Atlanta: Centers for Disease Control and Prevention and Pan-American Health Organization 1982: B17-35.
23. Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999; 37: 937-943
24. Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 2004; 103: 91-95
25. Center for Biologics Evaluation and Research, Food and Drug Administration, US Department of Health and Human Services. Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines. Rockville, MD: Food and Drug Administration, May 2007.
26. Reed L, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938; 27: 493-497
27. Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, Burke DS. Strategies for mitigating an influenza pandemic. Nature 2006; 442: 448-452
28. Germann TC, Kadau K, Longini IM Jr, Macken CA. Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci U S A 2006; 103: 5935-5940
29. Lin J, Zhang J, Dong X, et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006; 368: 991-997
30. Rümke HC, Bayas JM, de Juanes JR, et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 2008; 26: 2378-2388
31. 31. Treanor JJ, Wilkinson BE, Masseoud F, et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001; 19: 1732-1737 (Pubitemid 32175735)